95 related articles for article (PubMed ID: 23876214)
1. Erosive conjunctival and corneal inflammatory changes in a patient receiving weekly docetaxel for breast cancer.
Chalvatzis N; Manthou ME; Tzamalis A; Hytiroglou P; Dimitrakos S
Ocul Immunol Inflamm; 2014 Apr; 22(2):164-6. PubMed ID: 23876214
[No Abstract] [Full Text] [Related]
2. Erosive conjunctivitis and punctal stenosis secondary to docetaxel (taxotere).
Skolnick CA; Doughman DJ
Eye Contact Lens; 2003 Apr; 29(2):134-5. PubMed ID: 12695719
[TBL] [Abstract][Full Text] [Related]
3. Weekly docetaxel regimens and radiation pneumonitis.
Mauri D; Tzachanis D; Tsekoura P; Xanthakis I; Tsali L; Roumbkou S; Fountzilas G
J Support Oncol; 2008; 6(6):265-6. PubMed ID: 18724534
[No Abstract] [Full Text] [Related]
4. Bi-weekly docetaxel in the adjuvant treatment of node-positive or high-risk breast cancer patients: phase I study of the Shiga Breast Cancer Study Group.
Abe H; Ogawa H; Okino T; Kato M; Sako H; Sano H; Shimomatsuya T; Suwa H; Higashide S
Breast Cancer; 2009; 16(1):37-41. PubMed ID: 18493840
[TBL] [Abstract][Full Text] [Related]
5. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.
Nuzzo F; Morabito A; De Maio E; Di Rella F; Gravina A; Labonia V; Landi G; Pacilio C; Piccirillo MC; Rossi E; D'Aiuto G; Thomas R; Gori S; Colozza M; De Placido S; Lauria R; Signoriello G; Gallo C; Perrone F; de Matteis A
Crit Rev Oncol Hematol; 2008 May; 66(2):171-80. PubMed ID: 18160303
[TBL] [Abstract][Full Text] [Related]
6. [Fatal acute interstitial lung disease associated with docetaxel administration: about a case and review of the literature].
Brahmi SA; Youssef S; Ziani FZ; Afqir S
Pan Afr Med J; 2016; 24():119. PubMed ID: 27642457
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
Ardavanis A; Tryfonopoulos D; Orfanos G; Karamouzis M; Scorilas A; Alexopoulos A; Rigatos G
Onkologie; 2005 Nov; 28(11):558-64. PubMed ID: 16249641
[TBL] [Abstract][Full Text] [Related]
8. Weekly docetaxel in metastatic breast cancer patients: no superior benefits compared to three-weekly docetaxel.
Schröder CP; de Munck L; Westermann AM; Smit WM; Creemers GJ; de Graaf H; Stouthard JM; van Deijk G; Erjavec Z; van Bochove A; Vader W; Willemse PH
Eur J Cancer; 2011 Jun; 47(9):1355-62. PubMed ID: 21251813
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel for metastatic breast cancer: two consecutive phase II trials.
Campora E; Colloca G; Ratti R; Addamo G; Coccorullo Z; Venturino A; Guarneri D
Anticancer Res; 2008; 28(6B):3993-5. PubMed ID: 19192662
[TBL] [Abstract][Full Text] [Related]
10. Flagellate erythema induced by docetaxel.
Tallon B; Lamb S
Clin Exp Dermatol; 2008 May; 33(3):276-7. PubMed ID: 18201264
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel weekly with metastatic breast cancer.
Twelves C
Onkologie; 2007 Sep; 30(8-9):407-8. PubMed ID: 17848810
[No Abstract] [Full Text] [Related]
12. Generic docetaxel chemotherapy induced skin toxicities in breast cancer patient.
Elalami I; Ichou M
Pan Afr Med J; 2016; 24():164. PubMed ID: 27826363
[No Abstract] [Full Text] [Related]
13. Management of excessive tearing as a side effect of docetaxel.
Esmaeli B
Clin Breast Cancer; 2005 Feb; 5(6):455-7. PubMed ID: 15748466
[TBL] [Abstract][Full Text] [Related]
14. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer.
Rivera E; Mejia JA; Arun BK; Adinin RB; Walters RS; Brewster A; Broglio KR; Yin G; Esmaeli B; Hortobagyi GN; Valero V
Cancer; 2008 Apr; 112(7):1455-61. PubMed ID: 18300256
[TBL] [Abstract][Full Text] [Related]
15. Diffuse psoriasis induced by docetaxel in a 62-year-old woman with breast carcinoma.
Mapelli ET; Gualandri L; Menni S; Cerri A
G Ital Dermatol Venereol; 2016 Jun; 151(3):309-10. PubMed ID: 27176084
[No Abstract] [Full Text] [Related]
16. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P
J Clin Oncol; 2009 Aug; 27(22):3611-9. PubMed ID: 19470941
[TBL] [Abstract][Full Text] [Related]
17. Protracted administration of weekly docetaxel in metastatic breast cancer.
Kuroi K; Bando H; Saji S; Toi M
Oncol Rep; 2003; 10(5):1479-84. PubMed ID: 12883727
[TBL] [Abstract][Full Text] [Related]
18. Testing chemotherapy for breast cancer: timing is everything.
Hudis C
J Clin Oncol; 2005 Aug; 23(24):5434-6. PubMed ID: 16110004
[No Abstract] [Full Text] [Related]
19. Neutropenic enterocolitis associated with docetaxel therapy in a patient with breast cancer.
Rolston KV
Clin Adv Hematol Oncol; 2009 Aug; 7(8):527-8. PubMed ID: 19927979
[No Abstract] [Full Text] [Related]
20. High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer.
Stemmler J; Mair W; Stauch M; Papke J; Deutsch G; Abenhardt W; Dorn B; Kentenich C; Malekmohammadi M; Jackisch C; Leinung S; Brudler O; Vehling-Kaiser U; Stamp J; Heinemann V
Oncology; 2005; 68(1):71-8. PubMed ID: 15809523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
